↓ Skip to main content

Dove Medical Press

Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer

Overview of attention for article published in OncoTargets and therapy, October 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

policy
1 policy source
wikipedia
1 Wikipedia page
reddit
1 Redditor

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
29 Mendeley
Title
Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer
Published in
OncoTargets and therapy, October 2018
DOI 10.2147/ott.s176273
Pubmed ID
Authors

Liang Zeng, Yizhi Li, Lili Xiao, Yi Xiong, Li Liu, Wenjuan Jiang, Jianfu Heng, Jingjing Qu, Nong Yang, Yongchang Zhang

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 10%
Student > Master 3 10%
Researcher 3 10%
Student > Ph. D. Student 1 3%
Other 1 3%
Other 1 3%
Unknown 17 59%
Readers by discipline Count As %
Medicine and Dentistry 4 14%
Biochemistry, Genetics and Molecular Biology 3 10%
Agricultural and Biological Sciences 2 7%
Social Sciences 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 2 7%
Unknown 16 55%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2020.
All research outputs
#5,416,884
of 25,523,622 outputs
Outputs from OncoTargets and therapy
#268
of 3,021 outputs
Outputs of similar age
#98,501
of 355,040 outputs
Outputs of similar age from OncoTargets and therapy
#11
of 138 outputs
Altmetric has tracked 25,523,622 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,021 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 355,040 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 138 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.